Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supplemental Curosurf dose to prevent extubation failure in preterm infants with respiratory distress syndrome
2005-005371-15Phase 3Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Apr 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Proportion of preterm infants with extubation failure. Started Apr 2006; status: terminated.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2005-005371-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005371-15.